A Phase I/IIa Study of Safety and Efficacy Of Alpharadin With Docetaxel In Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Trial Profile

A Phase I/IIa Study of Safety and Efficacy Of Alpharadin With Docetaxel In Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Radium 223 chloride (Primary) ; Docetaxel
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results analysing effects of radium-223 with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer, presented at the 2017 Genitourinary Cancers Symposium.
    • 07 Jun 2016 Results (n=53) analyzing safety presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top